These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35229156)

  • 1. Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    Neville LF; Shalit I; Warn PA; Rendell JT
    J Antimicrob Chemother; 2022 May; 77(6):1706-1709. PubMed ID: 35229156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
    Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice.
    Reniguntla MK; Yedle R; Puttaswamy R; Puttarangappa P; Hiremath S; Pawar A; Nanjundappa M; Jayaraman R
    Curr Drug Metab; 2020; 21(2):132-139. PubMed ID: 32156232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
    Guo S; Li X; Li Y; Tong H; Wei M; Yan B; Tian M; Xu B; Shao J
    J Antimicrob Chemother; 2022 Dec; 78(1):141-149. PubMed ID: 36329646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
    Soubirou JF; Rossi B; Couffignal C; Ruppé E; Chau F; Massias L; Lepeule R; Mentre F; Fantin B
    J Antimicrob Chemother; 2015 May; 70(5):1466-72. PubMed ID: 25564564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
    Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.
    Alexandre K; Soares A; Chau F; Fantin B; Caron F; Etienne M
    J Antimicrob Chemother; 2019 May; 74(5):1323-1326. PubMed ID: 30689887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Delhi metallo-β-lactamase - type carbapenemases producing
    Grover SS; Doda A; Gupta N; Gandhoke I; Batra J; Hans C; Khare S
    Indian J Med Res; 2017 Jul; 146(1):105-110. PubMed ID: 29168466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
    J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Racine E; Nordmann P; Pantel L; Sarciaux M; Serri M; Houard J; Villain-Guillot P; Demords A; Vingsbo Lundberg C; Gualtieri M
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
    Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
    J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice.
    Jakobsen L; Lundberg CV; Frimodt-Møller N
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects.
    Straubinger M; Blenk H; Naber KG; Wagenlehner FM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3309-15. PubMed ID: 26976871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.